Ioflupan (123i) Rotop (Ioflupane (123i))

Ioflupane is a ligand that binds selectively to presynaptic dopamine transporters (DAT) on nigrostriatal neurons. The iodine‑123 radioisotope attached to the molecule emits gamma photons detectable by SPECT, producing a visual map of DAT density that reflects dopaminergic neuronal integrity.

The administered activity and volume are determined by the prescribing physician or nuclear medicine specialist based on patient weight, age, and the imaging protocol. Dosage is individualized and should follow local regulatory guidelines and the product’s prescribing information.

Safety data in pregnant or lactating women are limited, and the product is classified as pregnancy category unknown. It should be used only if the potential diagnostic benefit outweighs any possible risk to the fetus or infant, and breastfeeding may be discontinued as a precaution.

Enquiries are submitted through the product page at gnhindia.com, where the required quantity is entered. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Ioflupan (123i) Rotop uses iodine‑123, offering high‑resolution SPECT images and a well‑characterized safety profile. Alternative agents such as ^18F‑FP‑CIT are PET tracers, providing higher sensitivity but requiring PET facilities. Choice depends on equipment availability, regulatory status and clinical workflow.

The product must be stored refrigerated at 2–8 °C, protected from light, and kept in its original container. It should not be frozen or shaken. Prior to use, allow the vial to reach room temperature if required by the imaging protocol, and handle with radiation safety precautions.

Ioflupan (123i) Rotop is administered as a single intravenous injection under the supervision of a qualified nuclear medicine professional. After injection, a waiting period of typically 3–6 hours allows tracer uptake before SPECT imaging is performed.

Serious adverse events, though rare, include severe allergic reactions (anaphylaxis), significant hypotension, and radiation‑induced thyroid dysfunction. Immediate medical attention is required if symptoms such as difficulty breathing, rapid drop in blood pressure, or thyroid abnormalities occur after administration.

The tracer should be avoided in patients with known hypersensitivity to ioflupane or iodine‑123, those who have received iodine‑containing contrast media within the preceding 24 hours, and individuals in whom the diagnostic information would not alter clinical management. Caution is also advised for patients with severe renal impairment.